Repligen Rises as Investors Weigh M&A Progress and Fresh Bullish Signals

Repligen Corporation (RGEN) is up 4.7% today. Here is some analysis on what might have caused this price movement. ([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000119312526140150/2025_annual_report.pdf?utm_source=openai))

Analysis: The move appears tied to a mix of positive sentiment around Repligen’s pending BioLife Solutions acquisition, constructive management commentary at a September healthcare conference, and supportive analyst positioning. There does not appear to be a single new company press release driving the gain today, so part of the rally could also reflect investors extending recent momentum in the shares. ([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026061174/blfs-20260903.htm?utm_source=openai))

Details:

Repligen said in its second-quarter filing that it plans to acquire BioLife Solutions in a deal valued at about $1.5 billion, with closing expected in the fourth quarter of 2026 if customary conditions are satisfied. ([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000119312526323773/rgen-20260630.htm?utm_source=openai))

BioLife disclosed earlier in September that the U.S. antitrust waiting period under HSR had expired, removing one regulatory hurdle for the transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026061174/blfs-20260903.htm?utm_source=openai))

Management also presented at the Wells Fargo healthcare conference on September 9, keeping investor focus on the company’s bioprocessing growth outlook and integration strategy. ([investors.repligen.com](https://investors.repligen.com/press-releases/default.aspx?utm_source=openai))

Analyst sentiment has remained constructive, including a UBS Buy rating listed in September and earlier target increases from other firms during the summer. ([benzinga.com](https://www.benzinga.com/analyst-stock-ratings?tickers=RGEN&utm_source=openai))

Sources:

SEC, Repligen Investor Relations, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RGEN Insider Trading Activity

$RGEN insiders have traded $RGEN stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:

OLIVIER LOEILLOT (Chief Executive Officer) has made 0 purchases and 4 sales selling 17,719 shares for an estimated $2,993,346.
JASON K GARLAND (CFO) sold 530 shares for an estimated $79,500

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$RGEN Hedge Fund Activity

We have seen 261 institutional investors add shares of $RGEN stock to their portfolio, and 260 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ removed 3,125,867 shares (-64.1%) from their portfolio in Q2 2026, for an estimated $426,493,293
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,368,231 shares (+3153.5%) to their portfolio in Q2 2026, for an estimated $186,681,437
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 788,571 shares (+inf%) to their portfolio in Q2 2026, for an estimated $107,592,627
AMERIPRISE FINANCIAL INC added 650,918 shares (+70.4%) to their portfolio in Q2 2026, for an estimated $88,811,251
BLACKROCK, INC. removed 608,116 shares (-10.1%) from their portfolio in Q2 2026, for an estimated $82,971,347
HOLOCENE ADVISORS, LP added 583,302 shares (+82.3%) to their portfolio in Q2 2026, for an estimated $79,585,724
VESTAL POINT CAPITAL, LP removed 525,000 shares (-56.8%) from their portfolio in Q2 2026, for an estimated $71,631,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RGEN Analyst Ratings

Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 05/06/2026

To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.

$RGEN Price Targets

Multiple analysts have issued price targets for $RGEN recently. We have seen 9 analysts offer price targets for $RGEN in the last 6 months, with a median target of $160.0.

Here are some recent targets:

Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
Daniel Markowitz from Evercore ISI Group set a target price of $160.0 on 07/06/2026
Sidharth Sahoo from HSBC set a target price of $150.0 on 06/03/2026
Mike Polark from Wolfe Research set a target price of $145.0 on 06/02/2026
Dan Leonard from RBC Capital set a target price of $160.0 on 05/15/2026
Luke Sergott from Barclays set a target price of $160.0 on 05/06/2026
Casey Woodring from JP Morgan set a target price of $165.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.